Ruggedness of Visible-Residue Limits for Cleaning (Part II) - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ruggedness of Visible-Residue Limits for Cleaning (Part II)
The author challenges current detection methodologies.


Pharmaceutical Technology
Volume 35, Issue 3, pp. 122-128

Method


Table III: Residue concentrations.
A series of four previously studied compounds with established VRLs, listed in Table II, were diluted with methanol to sequentially lower concentrations. The coupons were prepared using 100 L of each solution resulting in four residue levels. The target concentrations were the four lowest concentrations shown in Table I: 20 g, 10 g, 5 g, and 1 g. One residue level was spotted per coupon. The spotted samples dried as elliptical residues. The resulting residue concentrations were calculated using the two elliptical radii in Table III based on the amount of residue spotted and the area of the resulting residue.


Table IV: Random coupon identification grid.
The coupons were arranged in a random order as shown in Table IV and Figure 1. Sixteen sample coupons and four solventblank coupons were prepared. In addition, five blank coupons brought the total matrix to 25 coupons in a five-by-five array.


Figure 1: Random coupon presentation.
The viewing parameters had been established previously: viewing distance was 18 in., viewing angle was 30, and ambient light intensity was > 200 lux (1). Eight observers participated in the study. The observers viewed the coupon array separately from one another to avoid influencing their individual choices. The results for the random determinations are presented in Table V.


Table V: Observer results.
After the observations were completed for the random coupon presentation, the residues were ordered sequentially, two observers were brought back to view the coupons, and their observations were recorded (see Table V). The sequential presentation was a confirmation for the previously established VRLs because the residue preparations were, in some cases, much lower than the reference VRL and because every residue preparation is slightly different based on the amount of compound weighed and the area of the resulting residue.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
30%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
8%
All of the above.
45%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here